Biotech Values

[mcbio]

Re: NVS/IDX-184

I'm surprised at NVS' decision, not surprised that the stock dropped, but also see this as a buying opportunity. I plan to dollar-cost average more into IDIX either tomorrow or early next week depending on what happens to the share price. While one should rightly wonder why NVS didn't want to license the compound, this doesn't mean that IDIX will be unable to find an interested party. Based on the PoC data they have already shown for IDX-184, I find it hard to believe that they won't be able to land a nice deal for the compound.